DOI 10.1515/dmdi-2013-0068 Drug Metab Drug Interact 2014; 29(1): 1–2
Editorial Gérard Siest
Systems medicine, stratified medicine, personalized medicine but not precision medicine The 7th Biologie Prospective Conference in Santorini, September 25–27, 2014, www.santorini2014.org For the first 5 years, the Santorini Biologie Prospective conferences were essentially geared to understanding the influence of genetic polymorphism on the variability of chronic, more specifically cardiovascular diseases. The corresponding evolutions in genomic tools were also discussed, and after 2008, pharmacogenomics became another major theme. Following the 2010 meeting, the second evolution was the creation of the European Society of Phamacogenomics and Theranostics, which is now a co-organizer. Finally, none of the major omics data now produced will be usable without a systems biology/ systems medicine approach, and this is the third evolution coming into the 2014 program with the P4 spirit of Personalized, Predictive, Preventive, Participatory medicine present everywhere, not only for patients but also, more importantly, for healthy people. “Personalized medicine is a medical model using molecular profiling technologies for tailoring the right therapeutic strategy to the right person at the right time, determining the predisposition to disease at the population level and delivering timely and stratified prevention” (World Health Organization, 2013). Stratified medicine is an intermediary situation before real personal medicine. We will discuss what is personal in personalized medicine, but in no way can we accept precision medicine. Medicine is not precise. For the clinical biochemist that I am, precision has a very specific definition in the interpretation of laboratory data including omics, i.e., proteomics data. It should be reported in any clinical trial with laboratory results! The aim of the conference is to bring together clinicians, laboratory medicine specialists, pharmacologists, hospital pharmacists, scientists from the pharmaceutical and biotechnological industries, geneticists, and epidemiologists to discuss how variability in the human genome could affect the protein expressed and the circulatory metabolites that may be helpful in the following:
–– Prediction of risks, particularly in multifactorial diseases: cardiovascular diseases, cancer, Alzheimer’s disease, etc. –– Evaluation of environmental risks: screening individual responses to nutrition, alcohol, tobacco, exercise, and lifestyle. –– Pharmacogenomics: measuring the individual response to drugs, including interactions with endogenous compounds. We have a homogeneous program split over 3 days, as follows: Thursday, September 25: SESSION I – From Systems Biology to Systems Medicine SESSION II – From Systems Medicine to Systems Pharmacology SESSION III – Understanding Cancer through Systems Medicine SESSION IV – Understanding Brain Health and Disorders through Systems Biology Friday, September 26: SESSION V – Applying Omics to Drug Discovery and Response SESSION VI – Translating Pharmacogenomics into Clinical Medicine SESSION VII – Metabolomic Tools for Clinical Implementation of Personalized Medicine SESSION VIII – Proteomic Biomarkers in Systems Pharmacology and Medicine Saturday, September 27: SESSION IX – Nutrition Environment and Human Health SESSION X – The Future of Healthcare with Omics SESSION XI – Implementation in Europe of Systems Medicine and Pharmacogenomic
Brought to you by | Brown University Rockefeller Library Authenticated | 128.148.252.35 Download Date | 5/29/14 6:11 AM
2 Siest: Systems medicine, stratified medicine, personalized medicine but not precision medicine After the first day showing the evolution of fundamental notions concerning systems medicine, the subject of applications in oncology and then neurology will be developed. The same evolutions will be reported, in four sessions on the second day, in pharmacogenomics for drug discovery and then for therapeutic monitoring and personalized medicine. Finally, on the third day, applications to human health will be discussed, including omics with environmental factors, including nutrition. All these major data are often stored in biobanks with the biological samples, and such organization will also be discussed at the end, with all the ethical limitations. Health and disease data banks should be cooperative since they contain millions of items of information important for the patient and for pharmaceutical industries that use them for the creation of new targeted drugs.
The conference will also host specific groups, e.g., the network of laboratories involved in pharmacogenomics, convened by Ron Van Schaik. We hope that many abstracts will be sent through the website at http://www.santorini2014.org. The last abstracts can be submitted until the end of May, but an intermediate selection will be made at the beginning of May 2014. Two awards will be given to the best posters. We look forward to seeing you in Santorini at the end of September. Prof. Gérard Siest
University of Lorraine, UMR INSERM U 1122, Nancy, France E-mail: [email protected]
Brought to you by | Brown University Rockefeller Library Authenticated | 128.148.252.35 Download Date | 5/29/14 6:11 AM
Editorial Gérard Siest
Systems medicine, stratified medicine, personalized medicine but not precision medicine The 7th Biologie Prospective Conference in Santorini, September 25–27, 2014, www.santorini2014.org For the first 5 years, the Santorini Biologie Prospective conferences were essentially geared to understanding the influence of genetic polymorphism on the variability of chronic, more specifically cardiovascular diseases. The corresponding evolutions in genomic tools were also discussed, and after 2008, pharmacogenomics became another major theme. Following the 2010 meeting, the second evolution was the creation of the European Society of Phamacogenomics and Theranostics, which is now a co-organizer. Finally, none of the major omics data now produced will be usable without a systems biology/ systems medicine approach, and this is the third evolution coming into the 2014 program with the P4 spirit of Personalized, Predictive, Preventive, Participatory medicine present everywhere, not only for patients but also, more importantly, for healthy people. “Personalized medicine is a medical model using molecular profiling technologies for tailoring the right therapeutic strategy to the right person at the right time, determining the predisposition to disease at the population level and delivering timely and stratified prevention” (World Health Organization, 2013). Stratified medicine is an intermediary situation before real personal medicine. We will discuss what is personal in personalized medicine, but in no way can we accept precision medicine. Medicine is not precise. For the clinical biochemist that I am, precision has a very specific definition in the interpretation of laboratory data including omics, i.e., proteomics data. It should be reported in any clinical trial with laboratory results! The aim of the conference is to bring together clinicians, laboratory medicine specialists, pharmacologists, hospital pharmacists, scientists from the pharmaceutical and biotechnological industries, geneticists, and epidemiologists to discuss how variability in the human genome could affect the protein expressed and the circulatory metabolites that may be helpful in the following:
–– Prediction of risks, particularly in multifactorial diseases: cardiovascular diseases, cancer, Alzheimer’s disease, etc. –– Evaluation of environmental risks: screening individual responses to nutrition, alcohol, tobacco, exercise, and lifestyle. –– Pharmacogenomics: measuring the individual response to drugs, including interactions with endogenous compounds. We have a homogeneous program split over 3 days, as follows: Thursday, September 25: SESSION I – From Systems Biology to Systems Medicine SESSION II – From Systems Medicine to Systems Pharmacology SESSION III – Understanding Cancer through Systems Medicine SESSION IV – Understanding Brain Health and Disorders through Systems Biology Friday, September 26: SESSION V – Applying Omics to Drug Discovery and Response SESSION VI – Translating Pharmacogenomics into Clinical Medicine SESSION VII – Metabolomic Tools for Clinical Implementation of Personalized Medicine SESSION VIII – Proteomic Biomarkers in Systems Pharmacology and Medicine Saturday, September 27: SESSION IX – Nutrition Environment and Human Health SESSION X – The Future of Healthcare with Omics SESSION XI – Implementation in Europe of Systems Medicine and Pharmacogenomic
Brought to you by | Brown University Rockefeller Library Authenticated | 128.148.252.35 Download Date | 5/29/14 6:11 AM
2 Siest: Systems medicine, stratified medicine, personalized medicine but not precision medicine After the first day showing the evolution of fundamental notions concerning systems medicine, the subject of applications in oncology and then neurology will be developed. The same evolutions will be reported, in four sessions on the second day, in pharmacogenomics for drug discovery and then for therapeutic monitoring and personalized medicine. Finally, on the third day, applications to human health will be discussed, including omics with environmental factors, including nutrition. All these major data are often stored in biobanks with the biological samples, and such organization will also be discussed at the end, with all the ethical limitations. Health and disease data banks should be cooperative since they contain millions of items of information important for the patient and for pharmaceutical industries that use them for the creation of new targeted drugs.
The conference will also host specific groups, e.g., the network of laboratories involved in pharmacogenomics, convened by Ron Van Schaik. We hope that many abstracts will be sent through the website at http://www.santorini2014.org. The last abstracts can be submitted until the end of May, but an intermediate selection will be made at the beginning of May 2014. Two awards will be given to the best posters. We look forward to seeing you in Santorini at the end of September. Prof. Gérard Siest
University of Lorraine, UMR INSERM U 1122, Nancy, France E-mail: [email protected]
Brought to you by | Brown University Rockefeller Library Authenticated | 128.148.252.35 Download Date | 5/29/14 6:11 AM
